Radiant Sage LLC, a provider of on-demand clinical trial imaging infrastructure solutions and services, today announced that it has expanded its operations into Europe through its partnership with Clearpoint Image Review Center (CIRC). Based in Oslo, Norway, CIRC is an imaging CRO (Contract Research Organization) that provides sponsors with extensive medical, operational and image management expertise in support of clinical trials.
CIRC will provide the facility and staffing resources for program management-based support for clinical studies in both the EU and U.S. They will also offer a wide range of services, including: audit support, document development and reader logistics to clinical study sponsor communications, site support and metrics reporting. In addition, CIRC will be able to leverage Radiant Sage's technology, staff and resources to support clients' clinical research studies.
Jeffrey Bowden, Radiant Sage's COO explained that "This teaming partnership represents an evolution in the industry, which is being driven by both advances in technology and the needs of clinical trial sponsors. Products like our Corelab-In-A-Box are virtually eliminating the need to have large laboratories of expensive imaging technology centrally maintained to process images and organize data for blinded reads. Now, trial sponsors can make much better use of regionally defined experts in a similar approach to that used in the CRO industry where medical monitors, program managers and clinical research associates are now de-centralized and regionally located providing a higher level of service to sponsors and clinical sites. The same can be done within the corelab industry, which is why this partnership with CIRC is an evolutionary step and will provide clinical trial sponsors with superior services, expertise and experience."
"Our clients are located throughout the world and having a partner in Europe will help us to better serve clinical trial sponsors with exceptionally experienced and regionally located staffing," said Venkatesan Thangaraj, Radiant Sage's CEO. "This partnership is a win-win for both companies, as well as our clients. We have complementary services and enable each other to expand our geographic footprints."
About Clearpoint Image Review Center
Clearpoint Image Review Center (CIRC) is an imaging CRO (Contract Research Organization) that provides sponsors with extensive medical, operational expertise in support of clinical trials. Originally established in 1999, CIRC brings 17 years of experience in the field of planning and executing Independent Blinded Reads for regulatory clinical studies. Its specialist team has successfully brought numerous clinical studies through U.S. FDA and EU inspections with no major findings. CIRC's method is based on proven standard operating procedures adding value and speed to clinical studies, shortening its clients' time to market. To learn more about CIRC, visit www.clearpoint-irc.com.
About Radiant Sage
Radiant Sage provides game-changing clinical trial imaging infrastructure solutions and services for organizations involved in drug discovery and research. Specifically designed for clinical trials, the company's solutions, RadClinica™, Core-Lab-in-a-Box™ and RadVista™ Viewer are extremely flexible and offer self-contained customization tools enabling rapid trial start and increased overall efficiency of the collection, distribution, processing, and analysis of clinical trial imaging data. The use of Radiant Sage's technologies provide sponsors with the ability to retain control of their clinical trials by leveraging these cost-effective image management solutions designed with real-time transparency in reporting at every level of the entire process. These secure and validated tools also offer increased image/data integrity over current corelab processes and meet all necessary compliance requirements. Founded in 2008, Radiant Sage is headquartered in Boston, Mass. For more information on Radiant Sage, visit www.radiantsage.com.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.